Navigation Links
Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
Date:10/20/2010

FREMONT, Calif., Oct. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection.

The Phase I open-label, dose-escalation study was initiated during the first quarter of 2010 to evaluate the safety, tolerability and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II). Enrollment has been completed, with no dose-limiting toxicities observed, in five of the six cohorts of Stratum I.  Dosing at the highest planned dose level has been initiated in this patient population. Up to 30 NAION patients will be enrolled in Stratum II. In addition to safety and pharmacokinetic assessments, changes in visual acuity and visual field following the administration of QPI-1007 will be measured.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "After escalating to the highest planned dose of QPI-1007 in patients with chronic nerve atrophy, we are excited to dose the first NAION patient in our ongoing clinical study of QPI-1007, which has demonstrated significant neuroprotective activity in preclinical studies."

About the Phase I Study

The Phase I, open-label, dose-escalation study will assess the safety, tolerability, and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II).  The study is expected to enroll up to 66 patients to receive a single intravitreal injection of QPI-1007 at varying doses with assessments of safety and tolerability for 12 months post-injection.  Secondary outcome measures include describing any anatomical changes in the optic nerve h
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
(Date:7/13/2014)... noninvasive optical imaging device developed at Cedars-Sinai can ... in the brain and are a classic sign ... investigators conducting a clinical trial in Australia. , ... in an oral presentation at the Alzheimer,s Association ... were invited by conference organizers to participate in ...
(Date:7/13/2014)... 13, 2014 Celebrity fitness trainer and ... a promotional partnership with Aqua Health Labs for their ... EPA supplement . The collaboration was recently announced live ... fitness trainer , actor, model, and a two time ... A-List celebrities, he has prepared stars including Demi Moore, ...
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... The Chicken Egg Production industry ... buoyed by stable demand for industry products as well ... a relatively affordable staple for most families across Canada; ... in line with the size of the population,” according ... new specialty egg products with enriched qualities, such as ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... solutions to support and enhance healthcare delivery.CHICAGO, March 31 ... by 35 years of healthcare IT experience, Siemens Healthcare ... ) will unveil its latest portfolio of healthcare ... Systems Society (HIMSS) 2009 Annual Conference and Exhibition in ...
... 31 CareFusion Corporation, the company that is expected ... clinical and medical products businesses, today filed a Form ... (SEC) that contains detailed information about the company as ... Cardinal Health,s plan to spin off at least 80 ...
... the 13 most prevalent serotypes associated with pneumococcal disease ... a division of Wyeth (NYSE: WYE ), ... Application (BLA) to the U.S. Food and Drug Administration ... CRM(197) Protein). Last year, the FDA granted Prevnar ...
... Difficult-to-remember generic drug names. Unregulated continuing medical ... two of the strategies used by some in ... of doctors, according to a Georgetown University Medical ... aimed at increasing physician access to unbiased information ...
... Tech Industry Veteran Will Focus on Broader Product ... 31 DecisionView, Inc., the leading provider of ... today announced that its Board of Directors has ... Chairman, President and CEO of DecisionView, effective immediately. ...
... Age 40 to 79 Have Experienced a Life ... a Spouse or Major Illness or DisabilityWomen Significantly ... EmotionallyAARP Financial Inc. President Says Understanding Emotions, Getting ... Finances in a Life CrisisAARP Financial Inc. Offers ...
Cached Medicine News:Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 2Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 3Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 4Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 5Health News:CareFusion Corporation Files Form 10 Registration Statement 2Health News:CareFusion Corporation Files Form 10 Registration Statement 3Health News:CareFusion Corporation Files Form 10 Registration Statement 4Health News:CareFusion Corporation Files Form 10 Registration Statement 5Health News:CareFusion Corporation Files Form 10 Registration Statement 6Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 2Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 3Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 4Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 5Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 6Health News:GUMC researcher creates first Web-interactive CME course for physicians on pharmaceutical marketing 2Health News:GUMC researcher creates first Web-interactive CME course for physicians on pharmaceutical marketing 3Health News:DecisionView Board of Directors Appoints James P. Scullion as CEO and President 2Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 2Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 3Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 4Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 5Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 6Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: